Article
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML.
Oncotarget - 17 May 2016
Wang Aoli, Wu Hong, Chen Cheng, Hu Chen, Qi Ziping, Wang Wenchao, Yu Kailin, Liu Xiaochuan, Zou Fengming, Zhao Zheng, Wu Jiaxin, Liu Juan, Liu Feiyang, Wang Li, Stone Richard M, Galinksy Ilene A, Griffin James D, Zhang Shanchun, Weisberg Ellen L, Liu Jing, Liu Qingsong
Abstract excerpt
The FLT3-ITD mutation is one of the most prevalent oncogenic mutations in AML. Several FLT3 kinase inhibitors have shown impressive activity in clinical evaluation, however clinical responses are usually transient and clinical effects are rapidly lost due to drug resistance. One of the resistance mechanisms in the AML refractory patients involves FLT3-ligand induced reactivation of AKT and/or ERK signaling via...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.